CL2020001635A1 - Análogos de incretina y sus usos. - Google Patents

Análogos de incretina y sus usos.

Info

Publication number
CL2020001635A1
CL2020001635A1 CL2020001635A CL2020001635A CL2020001635A1 CL 2020001635 A1 CL2020001635 A1 CL 2020001635A1 CL 2020001635 A CL2020001635 A CL 2020001635A CL 2020001635 A CL2020001635 A CL 2020001635A CL 2020001635 A1 CL2020001635 A1 CL 2020001635A1
Authority
CL
Chile
Prior art keywords
incretin analogs
activity
receptors
incretin
analogs
Prior art date
Application number
CL2020001635A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Tamer Coskun
Hongchang Qu
Lili Guo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2020001635A1 publication Critical patent/CL2020001635A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)

Abstract

Se proporcionan análogos de incretina que tienen actividad en cada uno de los receptores de GIP, GLP-1 y glucagón. Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan métodos para tratar enfermedades tales como diabetes mellitus, dislipidemia, hepatopatía grasa, síndrome metabólico, esteatohepatitis no alcohólica y obesidad.
CL2020001635A 2017-12-21 2020-06-17 Análogos de incretina y sus usos. CL2020001635A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21

Publications (1)

Publication Number Publication Date
CL2020001635A1 true CL2020001635A1 (es) 2020-10-16

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001635A CL2020001635A1 (es) 2017-12-21 2020-06-17 Análogos de incretina y sus usos.

Country Status (24)

Country Link
US (2) US11542313B2 (es)
EP (1) EP3727426A1 (es)
JP (2) JP6961838B2 (es)
KR (2) KR102622642B1 (es)
CN (1) CN111491658B (es)
AR (1) AR113486A1 (es)
AU (1) AU2018388962B2 (es)
BR (1) BR112020010244A2 (es)
CA (1) CA3084005C (es)
CL (1) CL2020001635A1 (es)
CO (1) CO2020006255A2 (es)
CR (1) CR20200255A (es)
DO (1) DOP2020000123A (es)
EA (1) EA202091290A1 (es)
EC (1) ECSP20032650A (es)
IL (1) IL275468A (es)
JO (1) JOP20200137A1 (es)
MA (1) MA51288A (es)
MX (1) MX2020006548A (es)
PE (1) PE20210162A1 (es)
PH (1) PH12020551025A1 (es)
SG (1) SG11202005606VA (es)
TW (2) TWI809515B (es)
WO (1) WO2019125938A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AU2020334993B2 (en) * 2019-08-19 2023-07-13 Eli Lilly And Company Methods of making incretin analogs
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AU2021241257A1 (en) * 2020-03-25 2022-10-13 Takeda Pharmaceutical Company Limited QD dosing of GIP receptor agonist peptide compounds and uses thereof
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AR125086A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas
CA3219647A1 (en) 2021-05-26 2022-12-01 The United Bio-Technology (Hengqin) Co., Ltd. Multi agonists and use thereof
CN115572326A (zh) * 2021-06-21 2023-01-06 广东东阳光药业有限公司 Glp-1、gcg和gip受体的三重激动剂
EP4358994A1 (en) 2021-06-23 2024-05-01 Eli Lilly and Company An incretin analog for use in glycemic control and weight management
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024067662A1 (zh) * 2022-09-28 2024-04-04 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945500B (zh) * 2008-06-17 2019-07-09 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
BRPI1013588A2 (pt) 2009-03-27 2016-04-19 Glaxo Group Ltd composição
CN102892425A (zh) * 2010-01-20 2013-01-23 西兰制药公司 心脏病症的治疗
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2012153196A2 (en) * 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
TR201902516T4 (tr) * 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
KR102310389B1 (ko) * 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
MA51288A (fr) 2021-03-31
CO2020006255A2 (es) 2020-05-29
WO2019125938A1 (en) 2019-06-27
KR20200088419A (ko) 2020-07-22
TWI744579B (zh) 2021-11-01
IL275468A (en) 2020-08-31
KR20220133304A (ko) 2022-10-04
AU2018388962B2 (en) 2020-11-19
TWI809515B (zh) 2023-07-21
CA3084005C (en) 2024-01-02
CR20200255A (es) 2020-07-12
KR102444783B1 (ko) 2022-09-19
EP3727426A1 (en) 2020-10-28
MX2020006548A (es) 2020-09-14
PE20210162A1 (es) 2021-01-26
PH12020551025A1 (en) 2021-09-06
BR112020010244A2 (pt) 2020-10-13
US20200331980A1 (en) 2020-10-22
AR113486A1 (es) 2020-05-06
CN111491658A (zh) 2020-08-04
CA3084005A1 (en) 2019-06-27
JP2022033724A (ja) 2022-03-02
JP2021506955A (ja) 2021-02-22
EA202091290A1 (ru) 2020-09-10
US20230203121A1 (en) 2023-06-29
ECSP20032650A (es) 2020-07-31
AU2018388962A1 (en) 2020-06-04
TW202202518A (zh) 2022-01-16
TW201938188A (zh) 2019-10-01
CN111491658B (zh) 2024-04-26
US11542313B2 (en) 2023-01-03
JP6961838B2 (ja) 2021-11-05
JOP20200137A1 (ar) 2022-10-30
KR102622642B1 (ko) 2024-01-10
SG11202005606VA (en) 2020-07-29
DOP2020000123A (es) 2020-08-31

Similar Documents

Publication Publication Date Title
CL2020001635A1 (es) Análogos de incretina y sus usos.
CO2020006253A2 (es) Análogos de incretina y sus usos
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
IL268702B (en) Use of a long-acting dual glp-1/glucagon receptor agonist for the treatment of non-alcoholic fatty liver disease
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
CO2017000510A2 (es) Constructos de car
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
SV2017005486A (es) Anticuerpos a tau y usos de los mismos
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DK3234107T3 (da) B-celler til in vivo-levering af terapeutiske midler
DOP2022000122A (es) Analogos de incretina y sus usos
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR112904A1 (es) Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas